It has been shown that NDRG1 deficiency significantly attenuates VEGFA-induced angiogenesis, and NDRG1 is closely correlated with plcγ1, suggesting that NDRG1-mediated plcγ1 activation may be a reliable therapeutic target for VEGFA-mediated vascular diseases, including cancers [8]. This evidence concerns the gene NDRG1 and cancer.